NRx Pharmaceuticals Appoints General HR McMaster to Company Board of Directors
RADNOR, Pa., May 27, 2021 / PRNewswire / – Today, NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced the election of the Honorable Herbert Raymond “HR” McMaster (LTG US Army, Ret.) As a member of the Board of administration of the company, from May 27, 2021.
NRx Pharmaceuticals Names General RH McMaster to the board of directors of the company
McMaster is currently the Fouad and Michelle Ajami Principal Investigator at the Hoover Institution of Stanford University. He graduated from the United States Military Academy and distinguished himself as a combat officer and chief during a 34-year career in the United States Army, after which he served as the 26th National Security Advisor (Assistant to the President for national security).
“NRx is committed to accelerating therapies for some of the sickest patients in our world and providing medicine for diseases where there is none,” said Lt. Gen. RH McMaster (Ret.), Member of the board of directors of NRx. “I look forward to working closely with my fellow Board members to help develop a long-term strategy to achieve NRx’s goals, realize the corporate vision, and contribute to global health security. “
In addition to his role at Hoover, McMaster currently serves as Stanford University as a Susan and Bernard Liautaud Fellow at the Freeman Spogli Institute and a lecturer at the Graduate School of Business. He is a successful author and historian who writes and lectures on military and diplomatic history, national security policy, and leadership.
“For decades I have admired General McMaster’s extraordinary leadership ability,” said Professor Jonathan javitt, MD, MPH, CEO and Chairman of the Board of NRx. “All of us at NRx look forward to learning and being inspired by his insight, wisdom and drive. ”
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a patient-focused, clinical-stage pharmaceutical company with more than 100 years of collective medicine development experience. NRx creates therapies to treat diseases where no drugs currently exist.
NRx plans to seek emergency use authorization from the United States Food and Drug Administration (FDA) to treat critical Covid-19 in patients with respiratory failure in May 2021. In addition, the FDA has granted the designation of revolutionary therapy and a special memorandum of understanding to develop NRX -101 in suicidal bipolar depression. The NRX-101 is currently in Phase 3 trials, with data readings expected in the first half of 2022.
Caution regarding forward-looking statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, development. of products, business prospects and market and industry trends and conditions, as well as company strategies, plans, objectives and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts and projections, as well as on assumptions made by the management of the company and on information currently available to the company. Words such as “expect”, “anticipate”, “should”, “believe”, “hope”, “target”, “plan”, “objectives”, “estimate”, “potential”, “predict”, “May,” “will”, “could”, “could,” “would”, “seek”, “plan”, “intend”, “must” and variations of these terms or the negative of these terms and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are, by their nature, subject to significant risks and uncertainties, many of which involve factors or circumstances beyond the control of the Company. These risks and uncertainties include , without limitation, our relatively limited operating history; our ability to develop, retain and motivate our people and to manage our growth; risks associated with general industry conditions and competition; general economic factors , including fluctuations in interest rates and exchange rates; the impact of the global epidemic of the novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and healthcare legislation in United States and internationally; global trends towards containing health care costs; technological advances, new products and patents obtained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately forecast future market conditions; manufacturing difficulties or delays; changes in laws, rules or regulations relating to any aspect of the Company’s business operations, or to general economic, market and business conditions; financial instability of international economies and sovereign risk; dependence on the effectiveness of company patents and other protections for innovative products; and exposure to litigation, including patent litigation, and / or regulatory actions. In addition, there can be no assurance with respect to the products in the pipeline that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If the underlying assumptions prove to be incorrect or if risks or uncertainties materialize, actual results may differ materially from those stated in forward-looking statements. The company assumes no obligation and does not intend to update or revise in any way any forward-looking statement, whether as a result of new information, future events or otherwise, except if required by applicable law. As a result of these and other risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur in the manner expected by the management of the Company, if at all. Therefore, you should not rely on any forward-looking statement, and all forward-looking statements are qualified herein by reference to the cautionary statements set forth above.
Senior Director, Corporate Communications
NRx Pharmaceuticals, Inc.
Show original content to download multimedia:http://www.prnewswire.com/news-releases/nrx-pharmaceuticals-names-general-hr-mcmaster-to-companys-board-of-directors-301300726.html
SOURCE NRx Pharmaceuticals